Validation of the RHL30 digital gene expression assay as a prognostic biomarker for relapsed Hodgkin lymphoma.
Lourdes CalventeRosemarie Tremblay-LeMayWei XuFong Chun ChanMichael HongTong ZhangHo-Young YhimJohn KuruvillaMichael CrumpVishal KukretiAnca PricaDean RegierMarco A MarraAly KarsanChristian SteidlDavid W ScottPeter SabatiniRobert KridelPublished in: British journal of haematology (2020)
Despite continuing improvements in the management of classical Hodgkin lymphoma (cHL), relapse remains associated with a risk of lymphoma-related mortality. The biological composition of relapse tumour biopsies shows interpatient variability, which can be leveraged to design prognostic biomarkers. Here, we validated the RHL30 assay, a previously reported gene expression model in an independent cohort of 41 patients with relapsed cHL. Patients classified as high-risk by the RHL30 assay had inferior failure-free survival (FFS) after autologous stem cell transplantation (2-year FFS 41% vs. 92%, P = 0·035). The RHL30 model is a robust biomarker that risk-stratifies patients considered for autologous stem cell transplantation.
Keyphrases
- hodgkin lymphoma
- stem cell transplantation
- gene expression
- free survival
- high dose
- end stage renal disease
- ejection fraction
- newly diagnosed
- acute lymphoblastic leukemia
- diffuse large b cell lymphoma
- dna methylation
- prognostic factors
- bone marrow
- peritoneal dialysis
- acute myeloid leukemia
- stem cells
- cell therapy
- low dose
- patient reported